The Food and Drug Administration issued a warning about the condition on Friday, May 16. In 209 cases tracked by the FDA, many described intense itching that appeared within days and disrupted their ...

"The claim that the FDA is suspending routine food safety inspections is false. FDA is actively working to ensure continuity of operations during the reorganization period and remains committed to ...

Gerard Criner, MD, FACP, FACCP, MATINEE investigator ... chronic obstructive pulmonary disease (COPD). Earlier today, the FDA approved mepolizumab (Nucala; GSK) as an add-on maintenance treatment ...

Roflumilast foam 0.3% trial investigator Jennifer Soung, MD, joined us to discuss the importance of this newly FDA-approved topical treatment for patients aged 12 years or older with scalp and body ...

Nasha is a Managing Editor for CNET, overseeing our sleep and wellness verticals. She is a nutrition, mental health, fitness and sleep science enthusiast. Her passion for mindful and holistic ...

This latest drug is among *** new group showing promise. The FDA granted accelerated approval for another experimental Alzheimer's drug called Lean IAB in January, Robert Eggy with the Alzheimer's ...

The FDA has cleared Fujirebio Diagnostics' Lumipulse blood test, marking the first of its kind for Alzheimer's diagnosis. This test measures pTau217 and β-amyloid 1-42 proteins to detect amyloid ...

Not all people should take Fujirebio's new test. The FDA says that it is "intended for patients presenting at a specialized care setting with signs and symptoms of cognitive decline" and is ...

MAKARY TALKS — FDA Commissioner Marty Makary announced Thursday that the agency will soon provide clear guidelines to vaccine manufacturers for annually updating their Covid-19 shots.

The test, called the Lumipulse G pTau217/ß-Amyloid 1-42 Plasma Ratio, is for adults 55 and older who are showing signs and symptoms of Alzheimer’s disease, the FDA announced Friday. It works by ...

GREENBELT, MD – A frustrated federal judge scolded ... He was detained in March by immigration officials near his home in Beltsville, Maryland, about a half hour outside of Washington.

The accelerated approval was based on data from the ongoing phase 2 LUMINOSITY study. The US Food and Drug Administration (FDA) has granted accelerated approval to Emrelis (telisotuzumab vedotin ...